Brokerages Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Target Price at $44.29

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has earned a consensus rating of “Moderate Buy” from the nine analysts that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $45.4286.

Several analysts recently issued reports on KNSA shares. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Friday, October 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Jefferies Financial Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, July 29th. Finally, Wedbush lifted their target price on shares of Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the company an “outperform” rating in a report on Monday.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ KNSA opened at $38.92 on Friday. The company has a 50 day simple moving average of $35.72 and a 200-day simple moving average of $29.60. The company has a market capitalization of $2.88 billion, a P/E ratio of 973.24 and a beta of 0.16. Kiniksa Pharmaceuticals International has a 1 year low of $17.82 and a 1 year high of $39.43.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million during the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, research analysts expect that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, COO Eben Tessari sold 12,368 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Tuesday, October 14th. The shares were sold at an average price of $37.67, for a total value of $465,902.56. Following the completion of the sale, the chief operating officer owned 28,684 shares in the company, valued at approximately $1,080,526.28. This trade represents a 30.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ross Moat sold 3,523 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $35.31, for a total transaction of $124,397.13. Following the completion of the sale, the insider owned 9,415 shares of the company’s stock, valued at $332,443.65. This trade represents a 27.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 596,839 shares of company stock worth $20,357,964 over the last quarter. Company insiders own 53.48% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Institutional investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after acquiring an additional 568 shares in the last quarter. Osaic Holdings Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International in the second quarter worth $31,000. USA Financial Formulas acquired a new position in shares of Kiniksa Pharmaceuticals International in the third quarter worth $32,000. Finally, US Bancorp DE acquired a new position in shares of Kiniksa Pharmaceuticals International in the first quarter worth $33,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.